Fed chair says central bank has ‘no tolerance’ for persistently high inflation
Policymakers are firmly committed to restoring price stability, says Kevin Warsh
IBM shares plunge over 23% as preliminary quarterly results miss forecasts
Revenue and adjusted earnings fall below market expectations as clients redirect spending toward servers, storage,…
US dollar maintains resilience against other currencies amid Middle East war in H1
Fed’s likelihood to maintain hawkish stance for extended period accelerates US Dollar Index’s rise as…
What Davey Rooney learnt building Boring Without You
From workplace bullying to 450 Priceline stores, Davey Rooney reflects on building skincare for the 70 per cent with combination skin. The post What Davey Rooney learnt building Boring Without You appeared first on Inside Retail Australia.
Why is Italy betting on its postal service to power AI?
Poste Italiane’s bid for Telecom Italia reflects Europe’s growing push to build sovereign digital infrastructure and reduce reliance on foreign tech providers. The post Why is Italy betting on its postal service to power AI.
Why Glossier is betting on its past to appeal to millennials again
The beauty brand is reviving its New York identity as part of a wider turnaround under CEO Colin Walsh. The post Why Glossier is betting on its past to appeal to millennials again appeared first on Inside Retail Australia.
The US$65,000 and US$1,850 question: Can we hold this level after CPI release?
The digital asset market currently presents a fascinating divergence in momentum as investors navigate a complex macroeconomic landscape. Bitcoin recently climbed 0.
Temasek-backed Seviora closes $400m investment fund
Seviora said it had about US$75 billion in assets under management as of December 31, 2025
TSMC eyes price increase for mature chip production
AI demand is spreading beyond high-performance computing chips to mature-node products, such as power management integrated circuits and power devices
How this founder is fixing pharma’s data bottleneck
Justin Byers, founder and CEO of Axio BioPharma argues pharma’s real bottleneck isn’t science. It’s broken data flow between labs and manufacturers.
